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Abstract: Niacin is a B-complex vitamin which has been used for decades for the management 
of mixed dyslipidemias and primary hypercholesterolemia. It decreases the risk of cardiovascular 
events either when used as a monotherapy or in combination with other lipid lowering 
  medications. However, a major limitation to its use is niacin-induced flushing occurring even 
with the extended-release formulations. Laropiprant, a selective prostaglandin-2 receptor 
  inhibitor, specifically targets the cascade of events causing the flushing. It has been recently 
used in combination with extended-release niacin. This article will review the early experience 
with this combination with focus on efficacy, safety, tolerability and current place in therapy. 
Early data are promising and suggest that more patients in clinical practice will benefit from 
niacin combined with laropiprant. Ongoing clinical trials will provide a better insight on the 
long-term safety of the drug and its efficacy for reducing cardiovascular events.
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Introduction
The management of mixed dyslipidemias and primary hypercholesterolemia is a 
  cornerstone in the management of patients with coronary artery disease (CAD).1 It is well 
known that elevated levels of low-density lipoprotein cholesterol (LDL-C), low levels of 
high-density lipoprotein cholesterol (HDL-C) and high triglycerides (TG) are risk fac-
tors for the formation and progression of coronary plaques (2, 3). Among lipid-altering 
therapies, lowering LDL-C cholesterol with statins remains the most commonly used 
strategy in clinical practice.4–6 It has been shown to decrease the incidence of major 
cardiovascular events by 25% to 35%. While intensive LDL-C lowering may result in 
further benefit, it is likely that even greater prevention of cardiovascular events will be 
achieved by also aiming to raise HDL-C and lower TG.
Considerable evidence suggests that even minor improvements in HDL-C levels 
may have a benefit on CAD risk. A meta-analysis by Gordon et al7 demonstrated that 
an increase of 1 mg/dL in HDL-C levels is associated with reduction in CAD risk by 
2% in men and 3% in women. This potentially beneficial effect of HDL-C on reduction 
of CAD risk relates to its major role in cholesterol transport from tissues to the liver, 
as well as potential anti-inflammatory, antithrombotic and antioxidative effects.8
Lowering TG levels may also reduce CAD risk.9–12 In an analysis of the Copenhagen 
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An elevated fasting TG level was found to be a strong risk 
  factor for ischemic heart disease, independent of known 
major cardiovascular risk factors, including low HDL-C. 
Similar observations were also reported from the Prospective 
  Cardiovascular Munster (PROCAM) study,10 which followed 
4849 men for up to 8 years. The association between high 
TG levels and CAD risk may be related to the presence of 
atherogenic TG-rich particles in the plasma or associated 
prothrombotic state.8,10,11 Conservative measures such as 
lifestyle changes may lower TG levels but medical therapy 
is to be considered when these measures fail to achieve 
  recommended therapeutic targets. Lipid-lowering guidelines 
currently recommend specific targeting of LDL-C with mild 
hypertriglyceridemia, with a greater focus on TG-lowering 
therapies when levels are more severely elevated.
A strategy targeting multiple lipid parameters will 
  potentially have the greatest benefit on CAD. This supports 
a joint statement from the American Diabetes Association 
(ADA) and American College of Cardiology (ACC) 
  recommending multiple risk factor modifications in the 
management of CAD.1 This management often requires 
the prescription of multiple drugs and relies to a major 
degree on patient’s adherence. The best treatment is one 
that is efficacious, safe, simple to use and is well tolerated 
by patients. This has led to an increased use of combination 
products in clinical practice to achieve better therapeutic 
outcomes.
Niacin is a water soluble vitamin which has been used for 
decades for the management of dyslipidemias,13 either alone 
or in combination with other agents. It has been shown to 
be efficacious for the reduction of cardiovascular events in 
  clinical trials.14–21 At therapeutic doses of 1500 to 2000 mg/day, 
niacin is efficacious for reducing LDL-C, TG and non-HDL-C 
cholesterol, while increasing HDL-C.22 Accordingly, niacin 
has the most potent HDL-C raising therapy among currently 
used lipid-modifying therapies. Furthermore, niacin is the 
only lipid-modifying therapy with a beneficial effect on 
levels of lipoprotein (a). However, given that flushing is 
commonly experienced at such doses, compliance is limited 
with traditional preparations. As a result, there has been 
considerable interest in developing niacin preparations that 
limit flushing, and therefore enable more patients to tolerate 
therapeutically effective doses. Laropiprant, is a prostaglandin 
receptor inhibitor, has been used to reduce niacin-induced 
flushing and recently has been used in a combination pill with 
extended-release niacin (ERN).
In this article, we will review the early experience with 
laropiprant and ERN, rationale for combination, efficacy and 
safety studies, patient’s adherence and the current place in 
therapy of this novel agent.
Niacin for the management  
of coronary disease
Pharmacology, mode of action, lipid  
and nonlipid effects of niacin
Niacin is an essential component of coenzymes required 
for tissue respiration. As a lipid-altering therapy, its main 
effect is thought to involve inhibition of hepatic synthesis 
of VLDL-C and its metabolite LDL-C.23 It is likely to raise 
HDL-C levels by reducing lipid transfer of cholesterol from 
HDL-C to VLDL-C and by delaying HDL-C clearance,23,24 
although its effects on apolipoprotein A-I metabolism remains 
to be completely elucidated. The HDL-C raising properties 
of niacin are usually seen with doses as low as 1000 to 
1500 mg/day,25 however, at doses of 1500–2000 mg/day, it 
also has additional improvements in lipid profiles,23,24 reducing 
LDL-C, VLDL-C, non-HDL-C, TG, and lipoprotein (a).26
The favorable effects of niacin on coronary plaques may 
be also exerted through its effects on nonlipid parameters as 
it reduces plasma fibrinogen levels,27 plasminogen activator 
inhibitor-1, monocyte chemotactic protein-1, vascular cell 
adhesion molecule-1, and increases adiponectin and has 
antioxidative and anti-inflammatory vascular effects.26,28 It 
may also reduce blood pressure contributing to the overall 
risk reduction in CAD.29,30
It is therefore not surprising that combination regimens 
including niacin have consistently been found to have a 
beneficial impact on progression of carotid intima-media 
thickness31,32 and coronary plaques.33
Efficacy studies: niacin  
and cardiovascular risk
The role of niacin in reduction of cardiovascular risk is well 
established.14,15,20 The Coronary Drug Project was among the 
first trials to assess the cardiovascular benefits of niacin. This 
1960s’ trial was placebo-controlled in which the use of niacin 
was associated with reduction in nonfatal myocardial infarction 
and death21 on both short-term and long-term follow-ups.16 
The Cholesterol-Lowering Atherosclerosis Studies (CLAS I 
and II) and Familial Atherosclerosis Treatment Study (FATS) 
showed either angiographic regression or slow progression 
of coronary plaques on high dose (4300 mg/day) niacin 
co-administered with colestipol.17,34 The observation that 
there is typically substantial plaque regression underlying 
the finding of regression on an angiogram further highlights Therapeutics and Clinical Risk Management 2010:6 185
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the benefits of niacin on arterial wall pathology. Similar 
observations were also made in the Arterial biology for the 
investigation of the treatment effects of reducing cholesterol 
(ARBITER) study, in which the addition of ERN on an ongo-
ing statin treatment slowed the progression of atherosclerosis 
at 12 and 24 months.31,32 Most recently, this benefit was further 
  demonstrated in ARBITER-6, in which niacin had a favorable 
impact on carotid itima-media thickness progression compared 
with ezetimibe in statin-treated patients.35 In addition to 
coronary stenosis regression, the HDL-C Atherosclerosis 
Treatment Study (HATS)33 showed that, compared to pla-
cebo, simvastatin plus niacin therapy significantly reduced 
cardiovascular events including coronary death, stroke, revas-
cularization, myocardial infarction and worsening ischemia. 
Reduction of ischemic heart disease mortality and overall 
mortality by combined treatment with niacin and clofibrate 
was also achieved in the Stockholm Ischemic Heart Disease 
  Secondary Prevention Study.18
Two major clinical trials on niacin effects on cardiovascular 
events are ongoing. The atherothrombosis intervention in 
metabolic syndrome with low HDL/high TG and impact 
on global health outcomes trial (AIM-HIGH) enrolled 
3300 patients with low HDL-C (40 mg/dL in men 
and 50 mg/dL in women) and high TG (150 mg/dL), 
not on statin therapy. Patients were randomized to ERN plus 
simvastatin or simvastatin therapy to test the value of ERN 
as an add-on to statin therapy for the reduction of major 
cardiovascular events. The completion date is expected to 
be in late 2010. Another major ongoing niacin trial is the 
Heart Protection Study – Treatment of HDL-C to Reduce the 
Incidence of Vascular Events (HPS2-THRIVE) trial which is 
evaluating 25,000 patients randomized to laropiprant 40 mg 
and ERN 2000 mg with simvastatin 40 mg and ezetimibe 
10 mg or to placebo with simvastatin 40 mg and ezetimibe 
10 mg. This is a 4 year trial with a primary objective to assess 
major cardiovascular events. The expected completion date is 
in 2012. In all, there is strong evidence that niacin is beneficial 
for the reduction of cardiovascular risk, either alone or in 
combination with other lipid-altering agents.
Niacin-induced flushing
Poor tolerability at doses producing significant lipid profile 
changes has limited the use of niacin in clinical practice. 
Flushing is frequent but other side effects such as pruritis, 
paresthesia, and nausea can occur in up to 20% of patients.14,24 
The flushing is most severe with the immediate-release 
formulations, while less common when released slowly. 
However, the slow-release formulations are associated with 
increased risk of hepatotoxicity at clinically significant 
doses.36 This has led to the development of an ERN with an 
8 to 12 hours absorption time (time to peak serum levels is 
4 to 5 hours), aiming to reduce the flushing and hepatotoxicity 
observed with the immediate and slow release preparations 
respectively. ERN is administered once daily, usually at bed 
time with a snack to reduce flushing. It is uptitrated starting at 
doses of 500 mg per day for 4 weeks, followed by increasing 
the dose to 1000 mg for 4 weeks and to 2000 mg 4 weeks 
later if well tolerated. Despite its better tolerability and less 
flushing, the long-term adherence on ERN is low.14,37,38 This 
is particularly true for patients on 2000 mg/day, with flushing 
occurring in up to 90% of patients in some observational 
studies.14 In a recent study using telephone encounters to 
assess compliance on niacin, a large proportion of patients 
(60%) prescribed ERN discontinued the drug or changed 
their doses to 500 mg/day or less after 3 months of initiation 
of treatment, whereas only 8% of the patients in the study 
  continued ERN at doses of 1500 mg/day or higher.37 
The findings in some centers of much higher long-term 
compliance rates (as high as 85% in our own experience on 
doses higher than 1500 mg/day) underscore the importance 
of patient education for maintenance of compliance. In fact, 
dedicated preventive cardiology nurses are in charge of 
patient education and long-term follow-up at our institution, 
whereas in the report by Kamal-Bahl37 only 50% of patients 
treated with ERN reported receiving appropriate education 
on the flushing and ways to avoid it. However, the time 
resources, intensive follow-ups with dedicated preventive 
cardiology nurses and the currently used 4-step titration 
regimen of ERN make the whole situation even more 
  complex in daily practice.
Laropiprant pharmacology and rationale 
for combination with ERN
Niacin-induced flushing has been demonstrated to be 
mediated by activation of prostaglandin-2 (PGD2) subtype 
receptor-1 (DP1 receptors) in vascular smooth muscle cells 
of dermal arterioles resulting in dilation, increased blood 
flow and subsequently flushing. Niacin appears to activate 
this cascade of events by stimulation of PG2 release from 
Langerhans cells.
Laropiprant is a highly selective DP1-receptor antagonist 
that was initially introduced as an anti-allergy agent.39 It is 
rapidly absorbed (Tmax¼ 0.8 to 2.0 hours) with a half-life of 
12 to 18 hours.40 It was noted in early trials of laropiprant that 
the drug reduces niacin induced flushing without affecting 
its therapeutic effects,41 suggesting that lipid-lowering and Therapeutics and Clinical Risk Management 2010:6 186
Hussein and Nicholls Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
flushing are mediated by two independent pathways. Also, 
it seemed that the blood pressure-lowering effect of niacin 
is independent from DP1-mediated vasodilatation.29 These 
observations stimulated interest in combining laropiprant and 
ERN. In early clinical trials, laropiprant was co-administered 
with ERN to dyslipidemic patients42 and significantly reduced 
flushing supporting its effectiveness in blocking PG2 subclass 
receptor D1. Subsequently, a combination pill with laropiprant 
and ERN (LERN) was developed, aiming to improve lipid 
profiles with the same efficacy of ERN while reducing side 
effects by use of laropiprant. A single tablet with fewer side 
effects would improve compliance and optimize outcomes. 
A major benefit of the improved tolerability is to eliminate the 
need for titration by replacing the 4-step titration strategy with 
a one-step increase in the dose from 1000 mg to 2000 mg/day 
of ERN. This concept of dose escalation was emphasized in 
early efficacy trials of LERN.
Early experience with laropiprant 
and ERN
Early efficacy studies
Data from early trials combining laropiprant and ERN was 
encouraging. In an initial phase II trial,42 patients were 
  randomized to ERN 1000 mg/day alone or with laropiprant. 
The first part (A) of the study randomized 154 dyslipidemic 
patients randomized to laropiprant 150 mg/day or placebo 
in a 9-week crossover study. After a 2-week washout, all 
122 patients who completed part A of the study entered 
part B, in addition to 290 patients who entered part B directly. 
In this second part of the trial, patients were randomized 
to placebo, ERN 1000 mg/day, or ERN 1000 mg/day with 
  laropiprant 18.75, 37.5, 75, or 150 mg for 4 weeks and then 
doses were doubled for the remaining 4 weeks of the study. 
In this study, the co-administration of laropiprant with 
ERN significantly reduced niacin-induced flushing without 
affecting the niacin effects on lipid parameters. Also, in 
this study, it was found that doses of 20 mg or 40 mg of 
laropiprant provide maximum protection against flushing 
associated with chronic use of niacin at doses of 1000 mg 
and 2000 mg respectively. Based on these initial findings, 
pharmacodynamics and pharmacokinetics studies led to 
the development of a LERN tablet containing 20 mg of 
laropiprant and 1000 mg of niacin. Subsequent studies used 
a 2-step escalation of the dose from LERN 1000 mg/20 mg 
to 2000 mg/40 mg, aiming to overcome the limitations of 
the 4-step uptitration regimen of ERN with a starting dose 
of 1000 mg/day in light of data suggesting that almost 1 in 
every 3 patients never titrate up beyond a starting dose of 
500 mg/day in the current ERN uptitration strategies.43
The early phase III trials focused on tolerability, safety 
and efficacy of LERN for lipid management. The major 
endpoints of these trials were the lipid effects and reduction 
in niacin-induced flushing at initiation and chronic treatment 
regimens, as well as safety and tolerability of the new 
1000 mg to 2000 mg dose escalation strategy. In an early 
phase III pivotal trial, LERN (40 mg of laropiprant/2000 mg 
of niacin) significantly improved lipid parameters compared 
to placebo, and resulted in 18.4% reduction in LDL-C, 20% 
increase in HDL-C, 25.8% reduction in TG, 19.8% decrease 
in non-HDL-C cholesterol, 18.8% decrease in ApoB and 
6.9% increase in ApoA-1.41 In this study, two-thirds of 
patients were on a statin at enrollment and were randomized 
to LERN, ERN or placebo. The 1000 mg starting dose was 
escalated to 2000 mg at 4 weeks and maintained for 20 
more weeks. The efficacy of LERN for lowering LDL-C 
as monotherapy or as a combination with a statin was the 
same, despite the lower LDL-C levels in the statin group at 
enrollment. The addition of laropiprant did not interfere with 
the efficacy of ERN and similar effects on lipid profiles were 
observed in the LERN and ERN groups.
Subsequently, a second phase III trial44 randomized 
1398 patients to LERN (20 mg/1000 mg), simvastatin or 
LERN plus simvastatin after a 6 to 8 weeks washout and 
4 weeks diet-placebo run in. Simvastatin was given at 10, 
20 or 40 mg. Four weeks after enrollment, all doses were 
doubled at the exception of simvastatin 40 mg. In this trial, 
the improvements seen in lipid profiles were more significant 
with LERN/simvastatin combination compared to simvastatin 
alone. In fact, the combination was more efficacious for 
reducing LDL-C (48% vs 37%, P  0.001), reducing TG 
(33% vs 15%, P  0.001) and increasing HDL-C (28% vs 
6%, P  0.001). In both studies, the effects of LERN on lipid 
profiles were independent of LDL-C, HDL-C and TG levels 
at enrollment, and consistent across age, gender, diabetes and 
concomitantly used types of statins subgroups.
These early studies supported the efficacy of LERN. It 
was necessary, however, to compare the tolerability of the 
2 steps uptitration strategy of LERN to the ERN 4 steps 
  titration in a head-to-head comparison. The clinical relevance 
is to assess the value of adding laropiprant with focus on 
patient acceptability, adherence and long-term compliance.
Patient-focused perspectives: assessing flushing, tolerabil-
ity and adherence to treatment The early trials implemented 
the use of a niacin flushing scale in order to objectively assess 
the flushing. The scale was developed initially and then Therapeutics and Clinical Risk Management 2010:6 187
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validated. It assesses flushing using an 11-question Flushing 
Symptom Questionnaire (FSQ). The degree of flushing is 
graded 1 to 10 based on frequency, duration, severity and 
bother of symptoms including warmth, paresthesia, itching 
and redness.45 This questionnaire was validated46 in an 8-week 
randomized, double-blinded, placebo-controlled trial. The 
FSQ items and specifically the Global Flushing Severity Score 
(GFSS) were found reliable and valid measures for objective 
assessment of flushing. Subsequently, the GFSS was used in 
clinical trials and became the surrogate of the FSQ.
Phase III studies evaluated the flushing profile of LERN 
during initiation of therapy where flushing symptoms are the 
most severe and during chronic maintenance of treatment 
where symptoms can be intermittent but unpredictable 
and bothersome. The flushing at initiation of therapy was 
  evaluated in the first phase III trial.41 Patients receiving LERN 
experienced less flushing symptoms than those receiving 
ERN with only 31% of patients experienced more than 
moderate flushing during the first week in the laropiprant 
group versus 56% in the ERN group. Similarly fewer patients 
experienced severe and extreme symptoms (14% vs 33%). 
At week 6, the symptoms experienced at initiation in patients 
in the LERN group decreased to a level similar to that in 
the placebo group, however patients in the ERN group 
  continued to have symptoms. These findings persisted until 
the completion of the trial (24 weeks), with overall reduction 
of moderate to severe duration of symptoms to 1 day per 
month in the laropiprant group compared to 1 day per week 
in the ERN group,45 suggesting that adding laropiprant did 
not only result in reduction of symptoms during induction 
of treatment but also in chronic maintenance. Also, the 
  persistence of symptoms over a 24 weeks period in the ERN 
group suggested that most of the patients do not develop 
tolerance and explains the high discontinuation rates in the 
first year in clinical practice.38
The third phase III trial14 compared the new 2-step 
dose escalation regimen of LERN to the currently used 
4-step ERN uptitration strategy. In this study, patients were 
  permitted to take aspirin or nonsteroidal anti-inflammatory 
drugs (NSAIDs) with niacin, which was taken with a meal. 
Patients on LERN escalation regimen had less moderate to 
severe flushing than those on ERN uptitration (GFSS equal or 
greater than 4). In the first 4 weeks, the addition of laropiprant 
reduced the flushing of ERN 1000 mg to less than the flushing 
experienced with ERN at the dose of 500 mg. In real world, 
this may correlate with more compliance on the starting dose 
of 1000 mg of niacin when laropiprant is added, which is 
clinically significant as most of the benefits on lipid profiles 
are seen with doses equal or higher to 1000 mg. Also, in this 
trial, symptoms in the laropiprant group decrease after week 5 
but persisted in the ERN group, which were consistent with 
findings from earlier phase III trials. The differences between 
the groups were even larger with time. At week 16, only 7% 
of patients on LERN reported more than moderate symptoms 
compared to 21% in the ERN group. Overall, starting at week 
5, patients on LERN were experiencing fewer symptoms 
whereas patients in the ERN group were having more symp-
toms with every uptitration step. Importantly, therapeutic 
doses of 2000 mg were reached by week 8 in the LERN group 
with only few patients experiencing more than moderate 
symptoms (GFSS  4). These differences were seen despite 
that patients were permitted aspirin or NSAIDs to alleviate 
symptoms. These drugs would have more effects in the ERN 
group, as they do not provide any additional benefits in terms 
of flushing beyond the effect of laropiprant.47 More patients in 
the ERN used aspirin or NSAIDs, suggesting that laropiprant 
provided a strong protection against flushing. Overall, the new 
regimen with laropiprant was more tolerated than the 4-step 
ERN uptitration regimen. Also, it is simple and would increase 
long-term compliance. In fact, the discontinuation of niacin 
because of flushing were 10% in the LERN group compared 
to 22% in the ERN group over a 24-week period. These find-
ings suggest superiority but do not necessarily reflect a real 
world situation. The discrepancy between discontinuation in 
the real world and clinical trials is underscored by the find-
ings that ERN discontinuation in clinical trials was not as 
high as in observational studies.45 In fact, dropout rates due 
to flushing in clinical trials were only modest (22, 38, 41, 42, 
48–55), but observational studies suggest dropouts as high as 
75%.38 In the niacin development program, early LERN trials 
were designed to assess flushing severity but not dropouts 
  secondary to flushing. Also, patients were encouraged to stay 
in the trials. Patients in clinical trials may have more compli-
ance than those in clinical practice, because of motivation, 
more education on side effects before enrollment as they go 
through informed consent process, exclusion of patients with 
history of flushing, close follow-up and short duration of trials. 
The exact discontinuation rates of LERN in clinical practice 
have yet to be determined. The data from early trials, however, 
are encouraging. One would expect more compliance and less 
discontinuation rates with more tolerability.
Safety
In a pooled analysis14 of 3 active phase III trials and 3 phase II 
1-year safety extensions, 1268 patients on ERN and 2548 
patients on LERN patients were evaluated for safety and Therapeutics and Clinical Risk Management 2010:6 188
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  occurrence of adverse events. The overall drug-related adverse 
events were the same in both ERN and LERN groups. The 
incidence of increase in liver enzymes to concentrations 
equal or 3 times the upper limit of normal were low, similar 
in both groups, reversible and not associated with clinical 
  hepatotoxicity. However, the occurrence of hepatotoxicity is 
not predictable and serial monitoring of liver enzymes is needed 
in clinical practice to screen for niacin-induced liver injury. 
The data from phase II and III trials showed that the addition 
of laropiprant did not have any clinically observable effect 
on muscle, in terms of either significant enzyme elevations or 
reports of myalgia. While one case of myopathy was docu-
mented in each of the ERN and LERN groups, these were 
associated with excessive physical activity.
Both groups demonstrated an increase of 4 mg/dL in 
fasting glucose levels, with only very few patients diagnosed 
with new-onset diabetes. While it is known that niacin may 
increase insulin resistance in susceptible patients,36 the 
  clinical significance of this is unknown. However, the benefits 
of niacin for reduction of cardiovascular events are likely 
to outweigh the risks associated with a small rise in fasting 
plasma glucose levels. This is supported by data suggesting 
that niacin has clear benefits on cardiovascular events in 
patients with hyperglycemia,56 as a result of its beneficial 
effects on lipid profile abnormalities that usually accompany 
diabetes. In addition to these side effects, niacin can increase 
uric acid levels and should be used cautiously in patients with 
gout. Moreover, it can cause hypotension and precipitate 
angina in patients treated with vasodilators.57
Overall, the data from preliminary trials suggest that the 
combination LERN is as safe as ERN. However, the endpoints 
from these trials were primarily the efficacy of laropiprant 
for the reduction of niacin-induced flushing. Also, there was 
a focus on ERN adverse events and there were no long-term 
safety data. Data from animal studies on long-term toxicity 
as well as early clinical human studies suggest that there are 
no safety concerns with the laropiprant component,14,40 but 
long-term safety has yet to be determined.
The concerns about long-term safety of LERN are 
not unreasonable. Given that prostanoid receptors are 
  ubiquitously expressed in the human body, it is possible that 
adverse effects may occur. Laropiprant is a selective PG2 
DP-1 receptor inhibitor, but it is unknown to what extent its 
selectivity for skin arterioles precludes any mechanism of 
action in other tissues. This may have implications in terms 
of currently unknown untoward adverse effects, in addition 
to blocking potential homeostatic pathways. The ongoing 
HPS2-THRIVE trial will likely address these safety concerns. 
When long-term safety data are available and raise no 
  concerns, the likelihood of LERN approval will be enhanced. 
Given that the safety of the preparation requires ongoing 
definition, in addition to relatively modest effects on lipid 
profiles, the Food and Drug Administration (FDA) rejected 
an early application for registration for the preparation. This 
highlights the ongoing need to understand more about its 
effects in humans before approval will be granted.
Conclusion: place in therapy
For decades, the only ways to prevent niacin-induced 
flushing were either conservative measures or nonselective 
  medications such as aspirin or NSAIDs. For the first time, 
we have the option of targeting the specific cascade of events 
causing the flushing. With the introduction of laropiprant, 
more patients in clinical practice will be able to benefit 
from the effects of niacin on lipid profiles and reduction in 
  cardiovascular events. The early experience with LERN is 
encouraging and shows that the drug is well tolerated and 
represents a new option for the management of dyslipidemias 
either as monotherapy or as a combination with other lipid-
altering medications especially statins. In fact, the best 
effects on lipid profiles were seen in patients treated with a 
  combination of LERN and a statin. The addition of laropiprant 
did not affect the lipid-modifying effects of niacin. However, 
it is still unknown whether the addition of laropiprant will 
affect the niacin effects on cardiovascular events.
Given the early data on its safety and efficacy, the LERN 
combination was approved by the European Union and 
other countries, but rejected by the FDA. Two major clinical 
endpoints have yet to be identified: the long-term safety and 
  efficacy for reduction of cardiovascular events. The initial trials 
had short duration follow-up and were not powered to assess 
cardiovascular outcomes. While we await the HPS2-THRIVE 
trial results, data on safety and efficacy may emerge from 
countries that have approved the drug. If HPS2-THRIVE 
demonstrate that LERN is efficacious for the reduction of 
cardiovascular events and raises no safety concerns, it will be 
likely then that the FDA will approve the drug.
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